Upcoming treatments in Parkinson's disease, including gene therapy.

  title={Upcoming treatments in Parkinson's disease, including gene therapy.},
  author={R. Rodnitzky},
  journal={Parkinsonism & related disorders},
  volume={18 Suppl 1},
  • R. Rodnitzky
  • Published 2012
  • Medicine
  • Parkinsonism & related disorders
  • Progress is being made in the development of three categories of therapy for Parkinson's disease: (1) Symptomatic, (2) Neuroprotective, (3) Neurorestorative. Evolving approaches to symptomatic therapy, already in clinical trials, include the use of adenosine 2(A) antagonists, novel glutamate antagonists, and serotonin receptor antagonists, the latter for the therapy of Parkinson's psychosis and/or levodopa-induced dyskinesias. Examples of promising neuroprotective therapies under evaluation… CONTINUE READING
    Old and new challenges in Parkinson's disease therapeutics
    • 38
    • Highly Influenced
    • Open Access
    A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
    • 66
    • Open Access
    Neuroprotective Treatments in Parkinson’s Disease
    miR-7 and miR-153 protect neurons against MPP+-induced cell death via upregulation of mTOR pathway
    • 66
    • Open Access


    Publications referenced by this paper.
    Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
    • 163
    Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
    • 312
    • Highly Influential
    • Open Access
    A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.
    • 48
    PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
    • 529
    • Open Access
    Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
    • 191
    • Open Access
    Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
    • 57
    Effect of deprenyl on the progression of disability in early Parkinson's disease.
    • 832
    Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains
    • 146
    • Open Access